This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.
It also contains a sub-study to enroll patients with severe COVID-19.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 250 participants
Primary Purpose: Treatment
Actual Study Start Date: May 23, 2019
Estimated Study Completion Date: December 28, 2021
For COVID-19 sub study*:
* The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
DAS181 4.5mg nebulized qd x 7 OR 10 days
Placebo nebulized qd x 7 OR 10 days
Drug: DAS181 OL
DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days < 40kg
Drug: DAS181 COVID-19
DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.